Compare Global X Lithium & Battery Tech ETF (LIT) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Lithium & Battery Tech ETF vs Viatris Inc — how do they compare? Global X Lithium & Battery Tech ETF trades at $69.15, while Viatris Inc trades at $17.15 (market cap $19.79B). The key difference: Viatris Inc pays a 2.83% dividend while Global X Lithium & Battery Tech ETF pays none, and Viatris Inc is trading nearer its 52-week high, Global X Lithium & Battery Tech ETF nearer its low. Which is the better fit depends on your goals.
| LIT | VTRS | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $91.62 | $17.39 |
52-Week Low | $40.80 | $8.74 |
Market Cap | — | $19.79B |
Enterprise Value | — | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LIT trades at $66.92, down 2.14% on the day, reflecting recent volatility amid shifting EV market dynamics. The ETF has doubled over the past year, driven by strong momentum in lithium, energy storage, and semiconductor sectors. Key holdings benefit from global EV sales growth, with June marking the fourth consecutive monthly increase. A dividend of $0.32 is scheduled for July 2026, providing income potential.
Outlook remains positive due to structural demand for lithium in EVs and renewables, though risks include Chinese export controls and U.S.-China trade tensions. Analyst sentiment is bullish, citing inflection in lithium markets and reshoring trends. Investors should monitor policy developments and supply chain stability for sustained gains.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
